NTRA
Price
$388.48
Change
+$9.56 (+2.52%)
Updated
Nov 3, 04:59 PM (EDT)
Capitalization
54.62B
2 days until earnings call
Intraday BUY SELL Signals
XGN
Price
$8.38
Change
-$0.01 (-0.12%)
Updated
Nov 3, 04:07 PM (EDT)
Capitalization
203.25M
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NTRA vs XGN

NTRA vs XGN Comparison Chart in %
View a ticker or compare two or three
VS
NTRA vs. XGN commentary
Nov 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRA is a StrongBuy and XGN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NTRA with price predictions
Nov 02, 2026

Aroon Indicator for NTRA shows an upward move is likely

NTRA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 286 similar instances where the Aroon Indicator showed a similar pattern. In 244 of the 286 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +6.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 22 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 65 cases where NTRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.986) is normal, around the industry mean (65.876). NTRA's P/E Ratio (-280.681) is considerably lower than the industry average of (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for XGN with price predictions
Nov 02, 2026

XGN in upward trend: price rose above 50-day moving average on October 28, 2026

XGN moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on XGN as a result. In 80 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for XGN just turned positive on October 29, 2026. Looking at past instances where XGN's MACD turned positive, the stock continued to rise in 31 of 36 cases over the following month. The odds of a continued upward trend are 86%.

The 10-day moving average for XGN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 155 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for XGN moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 28 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.638) is normal, around the industry mean (65.876). P/E Ratio (-10.232) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

FUNDAMENTALS RATINGS
NTRA vs XGN: Fundamental Ratings
NTRA
XGN
OUTLOOK RATING
1..100
2068
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
38
Fair valued
PROFIT vs RISK RATING
1..100
8100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
3534
P/E GROWTH RATING
1..100
8696
SEASONALITY SCORE
1..100
5032

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTRA's Valuation (6) in the Biotechnology industry is in the same range as XGN (38) in the null industry. This means that NTRA’s stock grew similarly to XGN’s over the last 12 months.

NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for XGN (100) in the null industry. This means that NTRA’s stock grew significantly faster than XGN’s over the last 12 months.

NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as XGN (99) in the null industry. This means that NTRA’s stock grew similarly to XGN’s over the last 12 months.

XGN's Price Growth Rating (34) in the null industry is in the same range as NTRA (35) in the Biotechnology industry. This means that XGN’s stock grew similarly to NTRA’s over the last 12 months.

NTRA's P/E Growth Rating (86) in the Biotechnology industry is in the same range as XGN (96) in the null industry. This means that NTRA’s stock grew similarly to XGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRAXGN
RSI
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 7 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
COMPARISON
Comparison
Nov 03, 2026
Stock price -- (NTRA: $378.92 vs. XGN: $8.39)
Brand notoriety: NTRA and XGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NTRA: 205% vs. XGN: 68%
Market capitalization -- NTRA: $54.62B vs. XGN: $203.25M
NTRA [@Medical Specialties] is valued at $54.62B. XGN’s [@Medical Specialties] market capitalization is $203.25M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Medical Specialties] industry is $21.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRA’s FA Score shows that 2 FA rating(s) are green while XGN’s FA Score has 0 green FA rating(s).

  • NTRA’s FA Score: 2 green, 3 red.
  • XGN’s FA Score: 0 green, 5 red.
According to our system of comparison, NTRA is a better buy in the long-term than XGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRA’s TA Score shows that 3 TA indicator(s) are bullish while XGN’s TA Score has 7 bullish TA indicator(s).

  • NTRA’s TA Score: 3 bullish, 5 bearish.
  • XGN’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, XGN is a better buy in the short-term than NTRA.

Price Growth

NTRA (@Medical Specialties) experienced а -6.42% price change this week, while XGN (@Medical Specialties) price change was +12.32% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.34%. For the same industry, the average monthly price growth was -5.26%, and the average quarterly price growth was +42.07%.

Reported Earning Dates

NTRA is expected to report earnings on Nov 05, 2026.

XGN is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Medical Specialties (-2.34% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
NTRA
Daily Signal:
Gain/Loss:
XGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

XGN and

Correlation & Price change

A.I.dvisor tells us that XGN and SHC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and SHC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XGN
1D Price
Change %
XGN100%
-2.33%
SHC - XGN
30%
Poorly correlated
-2.26%
NTRA - XGN
29%
Poorly correlated
-8.54%
NEO - XGN
27%
Poorly correlated
-5.12%
ADPT - XGN
26%
Poorly correlated
-5.93%
QDEL - XGN
26%
Poorly correlated
+5.89%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QDEF90.43-0.23
-0.26%
Northern Trust Quality Dividend Defensive ETF (QDEF)
VTEC96.86-0.28
-0.29%
Vanguard California Tax-Exempt Bond ETF (VTEC)
JUDO27.65-0.10
-0.35%
Janus Henderson U.S. Equity Enhanced Income ETF (JUDO)
EUO32.47-0.13
-0.41%
ProShares UltraShort Euro (EUO)
BOAT51.36-1.77
-3.33%
SonicShares Global Shipping ETF (BOAT)